CRISPR Therapeutics Participates in $100 Million Series A Financing for Seawolf Therapeutics
CRISPR Therapeutics AG participated in a $100 million Series A financing round for Seawolf Therapeutics, a newly emerged biotechnology company focused on DNA-based therapeutics.